Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- (-) Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- (-) High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- (-) Low-Value Care
- (-) Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- (-) Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Display Only
Showing 62 Results
Medicaid Best Price Reforms Can Encourage Innovative Payment Arrangements for Chronic Therapies
This NPC study extends previous work analyzing reforms to CMS’ Medicaid Best Price reporting rules to encourage the uptake of value-based purchasing agreements for chronic disease treatments.
ICER Misses…Again
The latest Unsupported Price Increase Report from ICER lacks balance, uses flawed methods and may harm patients.
Skyrocketing Deductibles Should Be a Focus of Open-Enrollment Season
The dizzyingly complex process of shopping for health insurance can obscure some of the most important factors in making a choice.
Expanding Pre-Deductible Coverage in HSA-Eligible Health Plans Benefits Patients
Expanding pre-deductible coverage under employer-led health plans would add few costs to health insurance premiums, according to a research report by the Employer Benefits Research Institute.
Employers Identify Good Practices for High-Deductible Health Plans
Employers can design a smarter high-deductible health plans by following good practices identified in NPC research.
Value Assessment’s ‘Leaky Bucket’ Problem
In Health Affairs Forefront, NPC outlines the challenges in assessing the value of new treatments and proposes a framework and recommendations to ensure patient access to new therapies and…
Creating a Dialogue or Just Playing for Headlines? Third Time Isn’t the Charm for ICER’s Pricing Report
Selectively picking the data to arrive at a convenient narrative — like the Institute for Clinical and Economic Review does in its third drug pricing report — should not be mistaken for good…
Chairman’s Blog: Five Questions Decision-Makers Should Be Asking About Health Technology Agencies
NPC Board Chair and BMS SVP Michael Ryan advises caution and careful consideration of the potential risks and tradeoffs for patients by using a centralized, government-run health technology…
Employers Embrace Opportunity to Increase Patient Access to Preventive Care for Chronic Conditions Through Pre-Deductible Coverage
Expanding pre-deductible health coverage for HSA-eligible plans could benefit millions of Americans suffering from chronic conditions as well as lower health care costs by reducing barriers to…
Celebrating the Use of Medicines in Keeping People Healthy
NPC President and CEO John O'Brien discusses how prescription medicines and the pharmacists who provided them helped people stay healthy at home during the pandemic.
Walking the Walk: Taking Needed Steps to Reduce Low-Value Care
Three leading researchers detail steps to reduce low-value care in the latest edition of The American Journal of Managed Care. Their approach complements a similar effort, the Roadmap for…
Chairman’s Blog: Let Data and Research Guide the Pricing and Access Policy Debate
NPC Board Chair and BMS SVP Michael Ryan reflects on the biopharmaceutical industry's role in solving global health challenges and how to address misunderstandings about what it takes to bring…
Savvy Employers Alter Status Quo to Address Drugs, Deductibles and Disincentives for Treatment
Thanks to an IRS rule, high-deductible health plans with health savings accounts can now cover an expanded list of preventive services and drugs before patients meet their plan’s annual out-of-pocket…
A Perfect Storm: How the Public and Private Sectors Came Together to Save the World From COVID
Health care policy experts gathered for a panel discussion, “If the NIH Funds the Research, Should There Be a 'Government Discount?” focused on key questions regarding government funding for…
ICER Pricing Report: Creating a Dialogue or Just Playing for Headlines?
Given declines in drug prices, the Institute for Clinical and Economic Review’s second report on drug pricing – focusing on a hand-picked, narrow group of medicines rather than the overall landscape …
Forging a Path Toward a More Stable and Patient-Centric Health System in 2021
In his commentary for Chain Drug Review, NPC Interim President and CEO Dr. Robert Dubois explores the steps we can take to improve our current health care system in the wake of the COVID-19 pandemic.
Empowering the Patient Voice in Value Assessment: Paving the Way for MCDA
The National Health Council (NHC) and National Pharmaceutical Council (NPC) co-hosted a webinar that explored how multi-criteria decision-making analysis (MCDA) can be used in value assessment.
Multi-Criteria Decision Analysis: A Way to Put Patient Concerns Front and Center in Value Assessment?
NHC and NPC released a white paper outlining multi-criteria decision analysis (MCDA), an approach to value assessment that may more holistically address patients’ concerns, experiences and treatment…